C4 Therapeutics, Inc. (CCCC)
3.49
-0.02
(-0.57%)
USD |
NASDAQ |
Sep 14, 10:56
C4 Therapeutics Max Drawdown (5Y) : 97.82% for Aug. 31, 2026
Max Drawdown (5Y) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Max Drawdown (5Y) Data
| Date | Value |
|---|---|
| August 31, 2026 | 97.82% |
| July 31, 2026 | 97.82% |
| June 30, 2026 | 97.82% |
| May 31, 2026 | 97.82% |
| April 30, 2026 | 97.82% |
| March 31, 2026 | 97.82% |
| February 28, 2026 | 97.82% |
| January 31, 2026 | 97.82% |
| December 31, 2025 | 97.82% |
| November 30, 2025 | 97.82% |
| October 31, 2025 | 97.82% |
| September 30, 2025 | 97.82% |
| August 31, 2025 | 97.82% |
| July 31, 2025 | 97.82% |
| June 30, 2025 | 97.82% |
| May 31, 2025 | 97.82% |
| April 30, 2025 | 97.82% |
| March 31, 2025 | 97.66% |
| February 28, 2025 | 97.66% |
| January 31, 2025 | 97.66% |
| December 31, 2024 | 97.66% |
| November 30, 2024 | 97.66% |
| October 31, 2024 | 97.66% |
| September 30, 2024 | 97.66% |
| August 31, 2024 | 97.66% |
| Date | Value |
|---|---|
| July 31, 2024 | 97.66% |
| June 30, 2024 | 97.66% |
| May 31, 2024 | 97.66% |
| April 30, 2024 | 97.66% |
| March 31, 2024 | 97.66% |
| February 29, 2024 | 97.66% |
| January 31, 2024 | 97.66% |
| December 31, 2023 | 97.66% |
| November 30, 2023 | 97.39% |
| October 31, 2023 | 97.27% |
| September 30, 2023 | 96.42% |
| August 31, 2023 | 94.55% |
| July 31, 2023 | 94.55% |
| June 30, 2023 | 94.55% |
| May 31, 2023 | 94.14% |
| April 30, 2023 | 94.14% |
| March 31, 2023 | 93.86% |
| February 28, 2023 | 89.98% |
| January 31, 2023 | 89.98% |
| December 31, 2022 | 89.98% |
| November 30, 2022 | 89.98% |
| October 31, 2022 | 89.98% |
| September 30, 2022 | 89.98% |
| August 31, 2022 | 89.98% |
| July 31, 2022 | 89.98% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Max Drawdown (5Y) Benchmarks
| Beam Therapeutics, Inc. | 89.12% |
| Rallybio Corp. | 98.93% |
| Q32 Bio, Inc. | 99.58% |
| Arrowhead Pharmaceuticals, Inc. | 88.96% |
| Oncolytics Biotech, Inc. | 92.83% |
Max Drawdown (5Y) Related Metrics
| Alpha (5Y) | -68.25 |
| Beta (5Y) | 2.937 |
| Annualized Standard Deviation of Monthly Returns (5Y Lookback) | 159.9% |
| Historical Sharpe Ratio (5Y) | -0.2602 |
| Historical Sortino (5Y) | -0.9247 |
| Monthly Value at Risk (VaR) 5% (5Y Lookback) | 35.97% |